- Home
- / Qualigen Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Qualigen Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-10-29
Market Capitalization
$2.8 M
2024-10-29
Revenue
$5 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.7M | 5.0M | ||||||||
| Cost of goods sold | 113.0K | |||||||||
| General and administrative expense | 6.4M | 4.9M | 4.8M | 5.4M | 4.6M | 11.7M | 10.8M | 6.1M | 4.2M | 8.8M |
| Operating expense total | 8.7M | 18.2M | 7.7M | 16.8M | 10.7M | 28.2M | 18.6M | 5.4M | 9.0M | |
| EBIT | (8.9M) | (18.4M) | (7.9M) | (17.0M) | (10.8M) | (22.7M) | (22.2M) | (11.3M) | (5.8M) | (13.2M) |
| EBIT margin, % | -445.1% | |||||||||
| Interest income | 40.9K | 60.9K | 40.2K | 126.8K | 123.1K | |||||
| Interest expense | 26.6K | 1.5M | 988.5K | |||||||
| Pre tax profit | (17.9M) | (21.3M) | (12.5M) | (6.2M) | (17.0M) | |||||
| Income tax expense | 5.0K | (265.1K) | (4.8K) | 6.3K | ||||||
| Net Income | (8.8M) | (18.4M) | (7.9M) | (16.9M) | (10.1M) | (17.9M) | (21.0M) | (13.8M) | (6.3M) | (19.5M) |
| EPS | (17.5) | (8.1) |